32 related articles for article (PubMed ID: 21745455)
1. DNA methylation of hematopoietic stem/progenitor cells from donor peripheral blood to patient bone marrow: implications for allogeneic hematopoietic stem cell transplantation.
Laurenzana I; De Luca L; Zoppoli P; Calice G; Sgambato A; Carella AM; Caivano A; Trino S
Clin Exp Med; 2023 Dec; 23(8):4493-4510. PubMed ID: 37029309
[TBL] [Abstract][Full Text] [Related]
2. Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders.
Awada H; Gurnari C; Visconte V; Durmaz A; Kuzmanovic T; Awada H; Tu ZJ; Cook JR; Bolwell BJ; Sobecks R; Kalaycio M; Bosler D; Maciejewski JP
Leukemia; 2024 Apr; ():. PubMed ID: 38684821
[TBL] [Abstract][Full Text] [Related]
3. Adult survivors' perceptions of their childhood and the influences of being treated for acute lymphoblastic leukaemia with allogeneic hematopoietic stem cell transplantation as a child: A phenomenographic study.
Arvidsson S; Brobeck E; Nygren JM; Jarfelt M; Aili K; Olsson M
Eur J Oncol Nurs; 2024 Apr; 70():102592. PubMed ID: 38669953
[TBL] [Abstract][Full Text] [Related]
4. Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial.
Estran S; Loschi M; Benachour S; Soldati A; Chiche E; Sammut R; Robert G; Jacquel A; Chibois J; Schneider S; Cluzeau T
Bone Marrow Transplant; 2024 Mar; ():. PubMed ID: 38509196
[TBL] [Abstract][Full Text] [Related]
5. IDALLO study: A retrospective multicenter study of the SFGM-TC evaluating the efficacy and safety of ivosidenib in relapsed IDH1-mutated AML after allogeneic hematopoietic cell transplantation.
Caillet A; Simonet-Boissard M; Forcade E; Robin M; Rubio MT; Couturier MA; Srour M; Maillard N; Devillier R; Huynh A; Bourhis JH; Simand C; Chantepie S; Boisson C; Kroemer M; Deconinck E; Berceanu A
Hemasphere; 2024 Mar; 8(3):e44. PubMed ID: 38469458
[No Abstract] [Full Text] [Related]
6. Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens.
Banna GL; Aversa S; Sileni VC; Favaretto A; Ghiotto C; Monfardini S
Crit Rev Oncol Hematol; 2004 Sep; 51(3):171-89. PubMed ID: 15331077
[TBL] [Abstract][Full Text] [Related]
7. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
8. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
9. Reduced-intensity conditioned allogeneic haematopoietic stem cell transplantation results in durable disease-free and overall survival in patients with poor prognosis myeloid and lymphoid malignancies: eighty-month follow-up.
Patil S; Spencer A; Schwarer A; Lewis I; Hertzberg M; Avery S; Wei A; Noutsos T; Paul E; Taouk Y; Muirhead J
Bone Marrow Transplant; 2010 Jul; 45(7):1154-60. PubMed ID: 19898502
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine and melphalan-based conditioning for patients with advanced hematological malignancies relapsing after a previous hematopoietic stem cell transplant.
Devine SM; Sanborn R; Jessop E; Stock W; Huml M; Peace D; Wickrema A; Yassine M; Amin K; Thomason D; Chen YH; Devine H; Maningo M; van Besien K
Bone Marrow Transplant; 2001 Sep; 28(6):557-62. PubMed ID: 11607768
[TBL] [Abstract][Full Text] [Related]
11. Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias.
Carella AM; Lerma E; Dejana A; Corsetti MT; Celesti L; Bruni R; Benvenuto F; Figari O; Parodi C; Carlier P; Florio G; Lercari G; Valbonesi M; Casarino L; De Stefano F; Geniram A; Venturino M; Tedeschi L; Palmieri G; Piaggio G; Podestà M; Frassoni F; Van Lint MT; Marmont AM; Bacigalupo A
Haematologica; 1998 Oct; 83(10):904-9. PubMed ID: 9830799
[TBL] [Abstract][Full Text] [Related]
12. Double reduced-intensity allogeneic hematopoietic stem cell transplantation: a retrospective study from the SFGM-TC.
Bay JO; Cabrespine A; Faucher C; Tabrizi R; Bordigoni P; Berceanu A; Coiteux V; Renaud M; Mialou V; Robin M; Kuentz M; Chevallier P; Dhédin N; Huynh A; Garban F; Witz F; Buzyn A; De Revel T; Galambrun C; Deconinck E; Contentin N; François S; Gratecos N; Blaise D; Michallet M;
Biol Blood Marrow Transplant; 2012 Feb; 18(2):250-6. PubMed ID: 21745455
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
